Xenon - NeuroproteXenon

Drug Profile

Xenon - NeuroproteXenon

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator NeuroproteXeon
  • Class Elements; General anaesthetics
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic brain damage
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic brain damage

Most Recent Events

  • 15 Mar 2016 Phase-II clinical trials in Brain damage (Combination therapy) in USA (Inhalation); before March 2016
  • 15 Mar 2016 Adverse events data from a phase II trial in Brain damage released by NeuroproteXenon
  • 15 Mar 2016 NeuroproteXeon plans a phase III trial for Brain damage in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top